Stargardt Disease Clinical Trials 2024

Stargardt Disease Clinical Trials 2024

Stargardt Disease research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in stargardt disease clinical trials today.

Trials for Age-Related Macular Degeneration Patients

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to stargardt disease

What are the top hospitals conducting stargardt disease research?

When it comes to advancing research and treatment options for Stargardt disease, several hospitals are leading the way. In Hagerstown, Cumberland Valley Retina Consultants has made significant strides with four active trials dedicated to this rare condition. Over the years, they have conducted a total of 16 trials since their first recorded investigation in 2012. Similarly, in Dallas, the Retina Foundation of the Southwest is actively engaged in four ongoing stargardt disease trials. With a history that dates back to their initial trial in 2012, they have completed an impressive tally of 20 studies related to this degenerative eye disorder.

Meanwhile, at Retina Consultants of Texas located in Bellaire and Retina Research Institute of Texas situated in Abilene—both renowned institutions—are also contributing significantly to the field of stargardt disease research. Each hospital currently conducts four active clinical trials focused on understanding and combating this genetic condition. Having embarked on their first stargardt disease trial more recently (in Bellaire's case dating back only to 2015), these hospitals have already achieved remarkable milestones by conducting a combined total of 24 and 34 trials respectively.

Notably last but certainly not least,making valuable contributions from East Florida Eye Institute based out Stuart,the establishment carrying three concurrent clinical tests intended towards fighting against Stargart diseases.It interestingly stood as one among those few pioneers who accomplished eleven previous investigations into such cases;dating its roots all way long ago till2005.

These leading hospitals across different locations showcase their commitment and dedication towards tackling Stargardt disease—a condition that affects individuals' central vision as a result of genetic mutations.With each new trial initiated,and with every advancement made,the hope for improved treatments grows brighter.The collective efforts being undertaken by these medical centers pave the path toward potential breakthroughs,serving as beacons for patients worldwide affected by this challenging disease

Which are the best cities for stargardt disease clinical trials?

When it comes to stargardt disease clinical trials, several cities have emerged as key hubs for research and innovation. Phoenix, Arizona, Dallas, Texas, Salt Lake City, Utah, Portland Oregon, and Gainesville Florida are among the top locations offering active trials in this field. These cities are conducting studies on various potential treatments such as IONIS-FB-LRx, Zimura, Avacincaptad pegol 2 mg intravitreal injection and Tinlarebant among others. With their commitment to advancing knowledge and finding effective therapies for stargardt disease sufferers, these cities provide invaluable opportunities for participation in groundbreaking clinical trials.

Which are the top treatments for stargardt disease being explored in clinical trials?

The search for effective treatments for Stargardt disease is ongoing, with several potential options being explored in clinical trials. Leading the pack is ALK-001, currently involved in two active trials specifically targeting Stargardt disease. This innovative treatment made its first appearance on the medical landscape in 2015 and has since garnered a total of two dedicated trials. Additionally, there are promising developments involving avacincaptad pegol 2 mg intravitreal injection and 'Scotoma awareness' training, both new entries to the field with one active trial each. These cutting-edge approaches offer hope for individuals living with Stargardt disease as researchers continue their quest for effective interventions.

What are the most recent clinical trials for stargardt disease?

Promising developments are arising in the field of Stargardt disease, with recent clinical trials offering hope for patients. One such trial involves an experimental treatment utilizing low doses, aiming to assess its effectiveness and safety in treating this condition. Another study focuses on Part 1 of a larger trial targeting Stargardt disease specifically. Additionally, researchers are investigating the potential benefits of JNJ-81201887 at higher doses as a therapeutic option for this debilitating disease. A Phase 3 trial is also underway, evaluating the efficacy and safety of Avacincaptad pegol through intravitreal injection. Lastly, gene therapy using vMCO-010 exhibits promise as it progresses through Phase 2 trials. These innovative approaches hold significant potential for improving outcomes and quality of life for individuals affected by Stargardt disease.

What stargardt disease clinical trials were recently completed?

Several clinical trials for Stargardt disease, a debilitating inherited eye disorder, have recently concluded. In May 2022, Sandoz completed a trial investigating the potential of SOK583A1 to address this condition. Similarly, Kodiak Sciences Inc wrapped up their KSI-301 study in June 2021. Additionally, Maturi Raj K., M.D., P.C., finished their RBM-007 Injectable Solution trial in the same month. These milestones highlight the ongoing efforts to find effective treatments for Stargardt disease and bring hope to those impacted by this progressive visual impairment.